3D Signatures to Present Positive Results for Prostate Cancer Liquid Biopsy

WINNIPEG, Manitoba, Feb. 21, 2017 -- 3D Signatures Inc. (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS") is pleased to announce that later today Dr. Sabine Mai, its co-founder and principle inventor, will present the results of a prospective blood-based prostate cancer pilot study using the Company’s proprietary TeloView^TM software platform. The results will be presented at the 24th International Molecular Medicine Tri-Conference in San Francisco, CA. Based on blinded blood samples, TeloView^TM correctly predicted the stability and aggressiveness of disease for each of the study’s 50 intermediate risk prostate cancer patients.

A prospective prostate cancer patient cohort was assessed to evaluate TeloView^TM’s potential to blindly stratify 50 intermediate risk prostate cancer patients (Gleason 7, PSA <20) and monitor their disease progression or stability. Patients were recruited after informed consent, blood was drawn and circulating tumor cells (“CTCs”) were isolated prior to radical prostatectomy. CTCs were isolated from blood samples from each of the 50 patients.¹ Surgery results correlated with the observed three-dimensional nuclear telomeric profiles from CTCs and indicated that the TeloView platform correctly identified each patient with stable vs. progressive disease (p=0.0175).

“These results are extremely encouraging,” stated Jason Flowerday, CEO of 3DS. “We believe that the TeloView^TM software platform is a disruptive technology. It is based on a universal structural biomarker, 3D telomere organization, that has generated impressive results across a number of diseases, with prostate cancer being one of our highest priorities.”

In previous clinical research, TeloView^TM has also demonstrated the ability to identify and profile multiple CTC clones within a single patient (heterogeneity)^1,2 as well as the ability to monitor and quantify changes to 3D telomere profiles as a result of treatment (before and after).³ Based on clinical data produced by Dr. Mai and her colleagues, 3DS believes that TeloView^TM is a promising candidate for development as an accurate, blood-based risk-assessment and monitoring platform for prostate cancer.

As announced on October 19, 2016, TeleView^TM will be included in a multicenter Canada-wide prostate cancer clinical trial, known as PRECISE, to identify and monitor prostate cancer patients suitable for active surveillance.

About 3DS

3DS (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) is a personalized medicine company with a proprietary software platform based on the three-dimensional analysis of chromosomal signatures. The technology is well developed and supported by 22 clinical studies on over 2,000 patients on 13 different cancers and Alzheimer’s disease. Depending on the desired application, this platform technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is designed to predict the course of disease and to personalize treatment for the individual patient. For more information, visit the Company’s new website at http://www.3dsignatures.com.

Forward-Looking Information

This news release includes forward-looking statements that are subject to risks and uncertainties. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements. All statements within, other than statements of historical fact, are to be considered forward looking. Although 3DS believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Risk factors that could cause actual results or outcomes to differ materially from the results expressed or implied by forward-looking information include, among other things: market demand; technological changes that could impact the Company’s existing products or the Company’s ability to develop and commercialize future products; competition; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; the ability to manage operating expenses, which may adversely affect the Company’s financial condition; the Company’s ability to successfully maintain and enforce its intellectual property rights and defend third-party claims of infringement of their intellectual property rights; adverse results or unexpected delays in clinical trials; changes in laws, general economic and business conditions; and changes in the regulatory regime. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements. 

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

¹ Adebayo Awe J, Saranchuk J, Drachenberg D, Mai S. Filtration-based enrichment of circulating tumor cells from all prostate cancer risk groups. Urol Oncol. 2017 Feb 12. pii: S1078-1439 (16) 30415.

² Awe JA, Xu MC, Wechsler J, Benali-Furet N, Cayre YE, Saranchuk J, Drachenberg D, Mai S. 3D telomeric analysis of isolated circulating tumor cells (CTCs) defines CTC subpopulations. Translational Oncology. 2013 2013 Feb; 6(1):51-65.

³ Wark L, Thomas Klonisch T, Quon H, Mai S. Three dimensional telomere signature dynamics in circulating tumor cells of early follow-up high-risk prostate cancer patients undergoing androgen-deprivation and radiation therapy. Urol Oncol. 2016 Dec 9. pii: S1078-1439 (16) 30332-5.

For further information, please contact:

Stephen Kilmer
Investor Relations
647-872-4849
[email protected]

OR

Hugh Rogers
VP Corporate Finance
604-250-6162
[email protected]